Retinoid X Receptor Modulation in Cancer Biology

The retinoid X receptor (RXR) is a master nuclear receptor that heterodimerises with numerous partners, including retinoic acid receptors, peroxisome proliferator-activated receptors and vitamin D receptor, to regulate transcriptional programmes governing cell proliferation, differentiation and metabolism. In cancer biology, modulation of RXR activity by synthetic ligands (rexinoids) or endogenous ligands alters tumour cell gene expression, impacting oncogenic signalling pathways, tumour microenvironment interactions and therapeutic sensitivity. RXR agonists have demonstrated antitumour effects across diverse cancer types by reprogramming transcription of genes involved in apoptosis, immune surveillance and extracellular matrix remodelling. Conversely, aberrant RXRα processing, such as N-terminal truncation (tRXRα), gives rise to non-genomic functions that activate cytoplasmic signalling cascades, promoting inflammatory and survival pathways. Advances in structural biology have elucidated RXR conformational states under agonist, antagonist and corepressor binding, offering insight into the design of modulators that selectively target RXR homodimers or heterodimers. The global significance of RXR modulation lies in its potential to integrate nuclear and membrane-proximal signalling events, thereby enabling combinatorial therapies that enhance chemosensitivity, overcome resistance mechanisms and harness immunomodulatory effects in oncology.

Research from Nature Portfolio

Recent studies examining a tumour-associated truncated form of RXRα (tRXRα) have uncovered its role in promoting colitis-associated colorectal cancer through activation of the NF-κB–IL-6–STAT3 axis in myeloid cells, revealing that tRXRα interacts with TRAF6 to induce pro-inflammatory gene expression. A novel small-molecule modulator derived from a non-steroidal anti-inflammatory precursor was shown to stabilise tRXRα and inhibit its oncogenic non-genomic actions, suppressing tumour growth in mouse models. Structural and biochemical investigations have further defined how N-terminal cleavage of RXRα alters tetramerisation and coactivator/co-repressor dynamics, highlighting conformational selection as a mechanism to inhibit PI3K–Akt signalling in cancer cells and inform the development of next-generation RXR-targeted therapeutics.

Retinoid X Receptor Modulation in Cancer Biology publication trend

The graph below shows the total number of articles in retinoid x receptor modulation in cancer biology across all publications each year (not limited to Nature Index journals).

Technical terms

Retinoid X receptor (RXR): A nuclear receptor that forms homo- or heterodimers with other nuclear receptors to regulate gene transcription in response to ligands.

Heterodimer: A complex of two different nuclear receptor proteins that bind DNA at specific response elements to modulate transcription.

Rexinoid: A synthetic ligand that selectively activates RXRs, used to modulate receptor activity in cancer and other diseases.

tRXRα: N-terminally truncated form of RXRα generated in tumour cells, which engages in non-genomic signalling to promote oncogenic pathways.

PI3K signalling: A cytoplasmic kinase cascade activated by receptor engagement that drives cell survival, growth and metabolism in cancer cells.

References

1. Synergistic Activation of VDR-RXR Heterodimers by Vitamin D and Rexinoids in Human Kidney and Brain Cells. Cells (2024).
2. The Novel RXR Agonist MSU-42011 Differentially Regulates Gene Expression in Mammary Tumors of MMTV-Neu Mice. International Journal of Molecular Sciences (2023).
3. Modulating retinoid-X-receptor alpha (RXRA) expression sensitizes chronic myeloid leukemia cells to imatinib in vitro and reduces disease burden in vivo. Frontiers in Pharmacology (2023).
4. Oncogenic potential of truncated RXRα during colitis-associated colorectal tumorigenesis by promoting IL-6-STAT3 signaling. Nature Communications (2019).
5. Structural Basis for Retinoic X Receptor Repression on the Tetramer*. Journal of Biological Chemistry (2011).
6. Modulation of nongenomic activation of PI3K signalling by tetramerization of N-terminally-cleaved RXRα. Nature Communications (2017).